Amyloidosis trials in New Zealand

3 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.

• Phase 3Taking people
  MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)

  Where

  Auckland, Christchurch

  Age

  18 years to 90 years

  People

  1,200 worldwide

  Run by

  Intellia Therapeutics

  See details and how to joinNCT06128629 · EU 2023-507220-23-00
• Phase 3Taking people
  TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy

  Where

  Auckland, Christchurch, Hamilton

  Age

  18 years to 85 years

  People

  1,750 worldwide

  Run by

  Alnylam Pharmaceuticals

  See details and how to joinNCT07052903 · EU 2024-519917-72-00
• Phase 2/3Enrolling by invitation
  Long-Term Follow-Up (LTFU) of Subjects Dosed With NTLA-2001

  Where

  Auckland

  Age

  18 years and over

  People

  72 worldwide

  Run by

  Intellia Therapeutics

  See details and how to joinNCT05697861 · EU 2023-507385-11-00